Quick answers
- What is pharma content authoring? Software that automates how pharma promotional content (emails, detail aids, banners, web pages) gets produced: assets are assembled from pre-approved, versioned modules and references on a consistent brand design system, inside one governed process with checks and reference management built in, instead of passing through manual handoffs between briefs, designers, agencies and reviewers.
- How is it different from general content or design software? Pharma content authoring platforms have compliance-specific features general tools don’t: MLR prechecks, claim and reference traceability, and localisation workflows built around global-to-local approval, not just design.
- What’s the difference between content authoring and self-service content authoring? Content authoring automates the production process itself: no manual handoffs, lost source files or hand-managed references. Self-service is what that automation makes possible: giving local brand and digital teams direct access, so they own their content.
- What are the best pharma content authoring platforms? It depends on the operating model you want to run. If the goal is self-service, with local brand and digital teams building their own content, Shaman is purpose-built for that model and the strongest option for it. If you’re evaluating for a centrally run or agency-led production model, weigh the candidates on the criteria in how to choose: Veeva or Salesforce integration, content volumes, and number of markets.
- Do pharma content authoring tools integrate with Veeva Vault? The strongest ones do, natively, so approved content and references stay governed in Vault PromoMats as the single source of truth while teams author on top of it.
- What is a modular content platform in pharma? A platform where content is built from pre-approved, reusable components (claims, references, layouts) rather than as one-off files, so approved elements get reused instead of rebuilt and re-reviewed each time.
- What is a pharma content operations platform? A broader term than content authoring alone. It covers the full lifecycle (authoring, MLR review, reuse, and localisation) as one connected system rather than separate, disconnected tools.
- What actually makes a platform work in practice? People, technology and process together, not tooling alone. The platform enables the work; adoption support and an operating model are what make it stick.
What is pharma content authoring?
Pharma content authoring is software that automates the production of compliant, branded content (emails, detail aids, banners, social assets, and web pages). Instead of a chain of manual handoffs between brief, designer, agency and reviewer, with source files that get lost or sit unversioned and little visibility of where an asset is, the whole process runs inside one governed tool: content is assembled from approved, versioned modules on a consistent brand design system, references are managed automatically, and checks and updates happen in the tool rather than by hand.
The category exists because pharma content has requirements general design tools don’t handle: every claim needs to trace back to an approved source, every reference needs to be current and correctly formatted, and content built for one market often needs to be adapted, not just translated, for another. A pharma content authoring platform builds those requirements into the tool itself, rather than leaving them to a separate manual check after the fact.
How is pharma content authoring software different from general design tools?
General design and content tools (think generic page builders or creative software) are built for flexibility. Pharma content authoring software is built for the opposite: guided flexibility. Enough freedom for whoever is authoring to build what the market needs, inside guardrails that keep every asset on-brand and compliant by construction. The difference shows up in a few specific, non-negotiable features general tools don’t have:
- Claim and reference traceability back to an approved source
- MLR prechecks before formal submission, not just after
- Modular, reusable content components instead of one-off files
- Native integration with the systems pharma already runs on (most commonly Veeva Vault PromoMats)
Content authoring and self-service content authoring: two levels of value
The two terms are often used interchangeably, but they describe different things, and they deliver value differently. One is about the process; the other is about who gets to run it.
Content authoring: automating the process
A content authoring solution automates the production process end to end. The manual handoffs between briefing, building and review disappear. Source files no longer get lost or sit unversioned on someone’s drive. Everyone can see where an asset is in the process. References are managed automatically, and checks and updates run inside the tool rather than by hand. A consistent brand design system is part of the same foundation: every asset is built on approved templates, components and styles, so brand consistency is a property of the process rather than something a central team has to police afterwards. The result is content that is more compliant, more consistent, more transparent and faster to produce, with far less reliance on third parties. This value applies whoever does the authoring: a central team, an agency, or a local marketer.
Self-service: handing that process to the people closest to the market
Once the process is simplified and automated, you can give access to local content teams. That is self-service content authoring, and the central idea is simple: local teams are closest to the market and fastest to respond. Self-service means taking back control. The platform is used directly by your local brand and digital teams, they own their content, and they stay market- and segment-responsive, shipping content with real impact instead of waiting on a production queue.
Shaman has a strong foundation to support this: across our customers, over 80% of licensed users are active and over 65% of all content is created in self-service. Self-service isn’t all-or-nothing either. Many teams run a hybrid model, where local content owners do most of the work themselves and are supported by an agency in specific cases.
What features actually matter in a pharma content authoring platform?
Self-service, guided authoring
The second level of value described above: once the process is automated, the platform can be opened up so local marketers build content directly rather than briefing someone else to build it for them. “Guided” is the key word. A blank canvas is still slow, because every decision has to be made from zero. A governed brand design system built into the tool removes that.
MLR acceleration
This means two different things, and it’s worth being specific: precheck features that catch compliance issues before formal submission, and review-side features (like clear approval-status visibility) that speed up the formal review itself. The strongest platforms do both, not just one.
Modular content and reuse
Pre-approved claims, references, and layout components that get assembled rather than rebuilt. This is what actually reduces MLR’s repeat workload, since previously approved elements don’t need re-review from scratch every time they’re reused correctly.
Veeva Vault integration
Most enterprise pharma content already lives in Veeva Vault PromoMats as the system of record. A content authoring platform that integrates natively, rather than requiring content to be copied out, edited elsewhere, and copied back in, keeps Vault as the actual single source of truth instead of one of several conflicting versions.
Localisation and global-to-local sharing
Content built globally needs to move to local markets fast, ready to adapt rather than rebuilt from scratch in every country.
Embedded AI
Increasingly standard, but worth distinguishing from generic AI: search across your own approved content library, translation support, and generation grounded in already-approved claims, not free-form output that then needs separate fact-checking against MLR standards.
To see how these features fit together in one product, take a look at Shaman Authoring.
What is a modular content platform in pharma, specifically?
A modular content platform is the part of a content authoring solution that handles reusable components: claims, references, layout blocks, and creative elements that are approved once and then assembled into different assets, rather than each asset being built and reviewed as a one-off. The practical benefit is downstream: content teams work faster because they’re configuring from approved parts, and MLR reviews less repeat material because reused, unchanged components don’t need re-review.
Modular content only works well when the operating model around it changes too. A library of reusable components doesn’t help if teams keep briefing agencies to build from scratch out of habit, or if there’s no clear ownership of what counts as “approved” for reuse. The technology enables modularity; adoption is what makes it actually reduce production time.
Do pharma content authoring tools integrate with Veeva Vault PromoMats?
The stronger platforms in this category do, and it matters more than it might first appear. Without native integration, content has to be copied out of Vault for editing and copied back in afterward, which creates multiple versions of the same asset and undermines Vault’s role as the single source of truth. With native integration, approved content and references stay governed inside Vault throughout the entire lifecycle, and teams author directly on top of it, with finished assets pushed back for review and approval in the same system.
From content authoring to content operations: what’s the difference?
Content authoring is one part of a bigger picture. A pharma content operations platform covers the full lifecycle (authoring, MLR review, content reuse, and localisation) as one connected system, rather than as separate tools that each solve one piece in isolation. The distinction matters because most of the time lost in pharma content production doesn’t happen inside any single tool. It happens in the handoffs between them: between authoring and review, between global and local teams, between “approved” and “findable enough to actually reuse.”
That’s also why content authoring alone, however good the platform, has a ceiling. The organisations that get the most out of it pair the technology with the operating model, governance, and adoption work to use it properly, which is exactly why this has become its own discipline (see Shaman’s Content Excellence Practice) rather than something a platform alone solves.
What are the benefits of a good pharma content authoring platform?
- Speed: an automated process removes the waiting between handoffs, so assets move in hours rather than through a production queue measured in weeks; with self-service, local teams remove the queue altogether
- Cost: less dependency on external agencies for routine asset production
- Compliance consistency: guardrails and prechecks reduce the avoidable errors that cause MLR rejection cycles
- Adoption: the best measure of whether a platform is actually working is whether people use it day to day, not whether it was purchased
- Brand consistency: a governed design system keeps output on-brand across every market without a central team reviewing every asset
- Scale: the same content operating model works whether you’re producing for 5 markets or 50
What this looks like in practice
What used to take weeks now takes days. We’ve cut our dependency on external teams, increased output, and taken full control of content production.
Read the full Idorsia case study. The adoption figures above matter more than the feature list: a platform that isn’t actually used doesn’t deliver any of the benefits above, regardless of what it’s capable of on paper.
What would that be worth for your own volumes? The Content Production ROI Calculator lets you set your own email, CLM, and market numbers to see the estimated time-to-market and cost difference between your current production model and a self-service approach.
Open the calculator →What actually determines whether a content authoring platform works?
Not the feature list. Most of the failure stories we hear from teams who’ve been through a difficult rollout come down to the same pattern: the software did what it was supposed to, and it still didn’t get used. What actually determines the outcome is three things working together, and most resources on this category only ever talk about one of them.
People
A platform that isn’t adopted delivers none of its benefits, regardless of what it’s technically capable of. Adoption comes from hands-on onboarding and ongoing support, not a training deck handed over at go-live. Ask any vendor for real adoption numbers, not just a feature demo: the gap between “purchased” and “used daily” is where most of the ROI quietly disappears.
Technology
Guided self-service, not a blank canvas, so local teams move fast without every decision needing separate sign-off. MLR prechecks and claim traceability built into content creation itself, not bolted on afterwards. Native integration with whatever system already holds your approved content (most commonly Veeva Vault PromoMats), so there’s one source of truth rather than several versions in circulation.
Process
Even good technology doesn’t fix a broken operating model by itself. The organisations getting the most out of a content authoring platform pair it with clear governance, defined ownership of what actually counts as “approved” for reuse, and a change management plan, not just a rollout date.
The process side is also the part a platform alone genuinely can’t solve, which is why it’s increasingly treated as its own discipline. Shaman’s own version of this is the Content Excellence Practice: strategic guidance and hands-on implementation together, rather than a platform sold on its own. The adoption figures above are what we track for exactly this reason.
How do you choose the best pharma content authoring platform for your organisation?
The best platform depends on the operating model you want to run. Shaman is built for the self-service model described above. Whichever model you’re going for, these are the criteria that actually differentiate options in practice:
- Does it integrate natively with your existing systems (most commonly Veeva PromoMats, Veeva CRM, Salesforce Marketing Cloud), or does content need to move between systems to get edited?
- Does it support true modular reuse, not just templates? Can claims and references be tracked and reused with traceability, or does “modular” just mean pre-built layouts?
- Are MLR features precheck-focused, review-focused, or both? These solve different problems and most platforms are stronger at one than the other.
- What does real-world adoption look like, not just what the platform can technically do? Ask for adoption rates and active-user numbers, not just feature demonstrations.
- Does it support global-to-local sharing, or only single-market production?
- Does the vendor help with the process and people side, or only ship the software? A platform without adoption support, training, and operating-model guidance puts all of that work back on your team. Ask what happens after go-live, not just what happens during implementation.
We go deeper on this evaluation process, including specific questions to ask vendors, in How to Choose the Right Content Authoring Solution and Is a Content Authoring Solution Right for You?
Common use cases for pharma content authoring platforms
Scaling omnichannel content
More channels and more personalisation both mean more content volume. Self-service authoring is what makes that volume achievable without proportionally growing the team.
Product launches and congress moments
When materials need to be built and updated fast in response to new data or competitive moves, waiting on an external production queue is the most expensive possible bottleneck.
Relieving MLR pressure
Not by removing MLR from the process, but by reducing how much avoidable rework reaches reviewers in the first place, through prechecks and reuse of previously approved elements.
Global-to-local rollout
Launching content across many markets without a separate build cycle in each one.
AI-ready content operations
Structured, tagged, traceable approved content is also what makes AI genuinely useful in a regulated environment later, since AI grounded in disorganised files just automates the disorganisation faster. See Shaman Atlas for how this looks in practice.
Frequently asked questions
What are the best pharma content authoring platforms?
It depends on the operating model you want to run. For a self-service model, where local brand and digital teams build their own content, Shaman is purpose-built and the strongest option. For centrally run or agency-led production, compare candidates on native integration with your existing systems (Veeva or Salesforce), genuine modular reuse with traceability, real-world adoption rates rather than feature lists, and whether MLR features cover prechecking, formal review, or both.
What is pharma content authoring software?
Software that automates the production of compliant, branded pharma content. It replaces manual handoffs, lost or unversioned source files and hand-managed references with one governed process: approved, versioned modules on a consistent brand design system, automated reference management, built-in checks and full visibility of where each asset is. Once that process is in place, it can be opened up to local teams as self-service.
What is the difference between content authoring and self-service content authoring?
Content authoring automates the production process: no manual handoffs, no lost or unversioned source files, automated reference management and checks, and full visibility of where each asset is. Self-service is the next step that automation makes possible: local brand and digital teams use the platform directly and own their content, because they are closest to the market and fastest to respond. Many teams run a hybrid model, with an agency supporting local content owners in specific cases.
What should life sciences companies look for in content authoring tools?
The same core requirements apply across pharma, biotech, and medtech: claim and reference traceability, MLR precheck capability, native integration with your content system of record (typically Veeva Vault), and genuine local-team adoption, not just technical capability on paper.
Do pharma content authoring tools integrate with Veeva Vault?
The stronger ones do, natively, keeping Vault PromoMats as the single source of truth throughout the content lifecycle rather than requiring content to be copied out for editing and copied back in, which creates version conflicts.
What is a modular content platform in pharma?
A platform for building content from pre-approved, reusable components (claims, references, layout elements) rather than one-off files. It reduces both production time and MLR’s repeat workload, but only delivers that benefit if the operating model around it changes too, not just the tooling.
What is a pharma content operations platform, and how is it different from content authoring?
Content authoring is one part of the picture: the tool for building assets. A content operations platform covers the full lifecycle (authoring, MLR review, reuse, and localisation) as one connected system. Most lost time in pharma content production happens in the handoffs between these stages, not inside any single tool, which is why the two terms increasingly get used together.
Curious how this compares for your setup?
Book a call with our team — we’ll walk through your current stack, volumes, and markets against the criteria above.
